Profil
Tina Abild Olesen is currently Vice Chairman at World Diabetes Foundation, Managing Director at Novo Nordisk Pharma GmbH, and Director at Embla Medical hf since 2024.
Formerly, Ms. Olesen was Senior Vice President-Global Diabetes Franchise at Novo Nordisk A from 2022 to 2025.
Education includes graduate and MBA degrees from Copenhagen Business School.
Aktive Positionen von Tina Olesen
| Unternehmen | Position | Beginn |
|---|---|---|
| EMBLA MEDICAL HF. | Direktor/Vorstandsmitglied | 01.03.2024 |
Novo Nordisk Pharma GmbH
Novo Nordisk Pharma GmbH Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products | Vorstandsvorsitzender | - |
World Diabetes Foundation
World Diabetes Foundation Investment Trusts/Mutual FundsMiscellaneous Functions as a foundation or endowment | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Tina Olesen
| Unternehmen | Position | Ende |
|---|---|---|
| NOVO NORDISK A/S | Corporate Officer/Principal | 01.08.2025 |
Ausbildung von Tina Olesen
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Novo Nordisk A/S
Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
Novo Nordisk Pharma GmbH
Novo Nordisk Pharma GmbH Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products | Health Technology |
Embla Medical hf
Embla Medical hf Medical SpecialtiesHealth Technology Provides non-invasive orthopedic products and support services | Health Technology |
Copenhagen Business School
Copenhagen Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
World Diabetes Foundation
World Diabetes Foundation Investment Trusts/Mutual FundsMiscellaneous Functions as a foundation or endowment | Miscellaneous |
















